Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
CCCC typically reports before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-12 | +$0.00 (+0.00%) | $0.16 (5.05%) | +$0.51 (+16.09%) | $0.82 (25.71%) |
| 2026-02-26 | +$0.01 (+0.36%) | $0.39 (14.08%) | -$0.08 (-2.88%) | $0.30 (10.79%) |
| 2025-11-06 | +$0.01 (+0.42%) | $0.14 (5.70%) | -$0.04 (-1.68%) | $0.25 (10.50%) |
| 2025-08-07 | +$0.62 (+31.63%) | $0.77 (39.29%) | -$0.08 (-3.10%) | $0.50 (19.38%) |
| 2025-05-07 | +$0.09 (+6.38%) | $0.23 (16.26%) | +$0.04 (+2.67%) | $0.19 (12.67%) |
| 2025-02-27 | -$0.05 (-1.89%) | $0.22 (8.11%) | +$0.11 (+4.23%) | $0.27 (10.19%) |
| 2024-10-31 | -$0.20 (-3.62%) | $0.54 (9.82%) | +$0.28 (+5.25%) | $0.52 (9.76%) |
| 2024-08-01 | -$0.02 (-0.30%) | $0.85 (12.65%) | -$0.26 (-3.89%) | $0.49 (7.34%) |
| Avg Abs Move | 5.58% | 13.87% | 4.97% | 13.29% |
Historical price action around CCCC earnings shows significant volatility, with an average absolute Day 0 move of 5.58% and Day +1 move of 4.97%. The most dramatic reaction came after the August 2025 report, when the stock surged 31.63% on Day 0 before pulling back 3.10% the following session. More recently, the May 2026 earnings triggered a 16.09% Day +1 rally, demonstrating that positive surprises can generate substantial momentum.
The Day 0 trading range averages 13.87%, indicating considerable intraday volatility as investors digest results and management commentary. Day +1 ranges average 13.29%, suggesting the initial reaction often extends into a second day of active trading. Notably, the direction of moves has been mixed—while recent quarters (May and November 2025) saw positive reactions, other reports triggered initial declines that later reversed.
Investors should prepare for a potential 5-6% move in either direction on earnings day, with the possibility of extended volatility into the following session. The stock's tendency toward large Day 0 ranges suggests that options premiums are likely elevated heading into the report, and that patient traders may find better entry points after the initial volatility subsides.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 16) |
| Expected Move | $0.17 (4.70%) |
| Expected Range | $3.45 to $3.79 |
| Implied Volatility | 126.25% |
The options market is pricing an expected move of 4.70% (±$0.17) through the August 21 expiration, which sits below the stock's average historical Day 0 move of 5.58% and well below the 13.87% average intraday range. This suggests options may be underpricing potential volatility, particularly given CCCC's history of double-digit percentage swings around earnings.
Part 3: What Analysts Are Saying
Analyst sentiment on C4 Therapeutics is overwhelmingly bullish, with the stock carrying an average recommendation of 4.75 out of 5.0—firmly in Strong Buy territory. The breakdown shows 7 Strong Buy ratings, 0 Moderate Buys, 1 Hold, and no Sell ratings among the 8 analysts covering the stock. This represents unchanged sentiment from one month ago, indicating stable conviction in the company's prospects despite recent market volatility.
The consensus price target of $13.33 implies 268% upside from the current price of $3.62, with individual targets ranging from a low of $7.00 (93% upside) to a high of $30.00 (729% upside). The wide range reflects differing views on the probability and timeline of clinical success, but even the most conservative target suggests substantial appreciation potential.
The stability in analyst ratings over the past month—with no upgrades, downgrades, or estimate revisions—suggests the Street is in a "wait and see" mode heading into earnings. The unchanged sentiment trend indicates analysts are comfortable with their current views and are likely waiting for tomorrow's results and management guidance before making any adjustments. The concentration of Strong Buy ratings, combined with price targets that imply multi-bagger potential, reflects optimism about CCCC's clinical pipeline and platform technology, even as the company continues to operate at a loss.
Part 4: Technical Picture
The Barchart Technical Opinion currently shows a Buy signal at 40% strength, unchanged from last week but down from 100% Buy one month ago. This deterioration suggests near-term momentum has weakened considerably, with the stock losing technical support as it has pulled back from recent highs.
Timeframe Analysis:
- Short-term (Hold): Neutral reading indicates the immediate trend has stalled, with neither bulls nor bears in control heading into earnings
- Medium-term (50% Buy): Moderate buy signal suggests the intermediate trend remains constructive despite recent weakness
- Long-term (100% Buy): Strong buy signal confirms the broader uptrend remains intact, with the stock well above its 200-day moving average
Trend Characteristics: The combination of Average strength and Weakest direction indicates CCCC is in a consolidation phase within an established uptrend, with momentum fading as the stock digests recent gains ahead of the earnings catalyst.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $3.57 | 50-Day MA | $3.92 |
| 10-Day MA | $3.56 | 100-Day MA | $3.41 |
| 20-Day MA | $3.69 | 200-Day MA | $2.88 |
CCCC is trading at $3.62, positioned above its 5-day ($3.57), 10-day ($3.56), 100-day ($3.41), and 200-day ($2.88) moving averages, but below its 20-day ($3.69) and 50-day ($3.92) averages. This configuration suggests the stock is in a short-term pullback within a longer-term uptrend. The 50-day average at $3.92 represents immediate resistance, while the 100-day at $3.41 provides nearby support. The technical setup is moderately supportive heading into earnings—the stock has room to run if results impress, but the recent loss of short-term momentum means a disappointment could trigger a test of the $3.41-$3.56 support zone. The 25% gain from the 200-day average provides a cushion, but also means some investors may be quick to take profits if the report fails to justify current valuations.